|
| Authors | Number
of subjects | Evaluation times | Drug | SNPs | Findings |
|
| Padiukov et al. (2003) | 123 | 3 months | Etanercept | −308A/G | Nonsignificant association between genotypes and response to treatment |
|
| Mugnier et al. (2003) | 59 | 22 weeks | Infliximab | −308A/G | Patients with −308G/G genotype are better infliximab responders than patients with −308A/A or A/G genotype |
|
| Khang et al. (2005) | 70 | 12 weeks | Etanercept | −857C/T | −857T allele is related to a significant better response to etanercept respect to the homozygotes CC allele |
|
| Fonseca et al. (2005) | 22 | 56 weeks | Infliximab | −308A/G | After 24.8 weeks of therapy the −308G/G patients had significantly better response than −308A/G subjects |
|
| Seitz et al. (2006) | 86 (54 RA, 10 psoriatic arthritis, 22 ankylosing spondylitis) | 24 weeks | Infliximab (no. 63)
Etanercept (no. 13)
Adalimumab (no. 10) | −308A/G | Patients with −308G/G genotype are better responders than those with A/A and A/G genotype independent of the treated rheumatic disease |
|
| Guis et al. (2007) | 86 | 6 months
12 months | Etanercept | −308A/G | −308G/G genotype is associated with a better response to etanercept respect to −308A/G genotype |
|
| Chatzikyriakidou et al. (2007) | 58 | Retrospective
study | Infliximab | −857C/T
−308G/A
−238G/A 489G>A | No independent polymorphism predict patients’ response to anti-TNF-α therapy |
|
| Micheli-Richard et al. (2008) | 380 | 12 months
| (i) Adalimumab + methotrexate (no. 182)
(ii) Adalimumab + other modifier drug (no. 96)
(iii) Adalimumab (no. 102) | −238A/G
−308A/G
−857C/T | The −238G/G, −308G/G, −857C/C alleles are significantly associated with a lower response to treatment with ADA + MTX |
|
| Pinto et al. (2008) | 113 | 30 weeks | | −308G/A
−238G/A | No association between genotypes and clinical response to therapy |
|
Infliximab + MTX |
|
| Marotte et al. (2008) | 198 | 6 months | Infliximab + MTX | −308A/G | The −308 SNP was not associated with the response to infliximab. The level of circulating TNF-α bioactivity is higher in −308A/A or A/G patients than that in G/G |
|
| Maxwell et al. (2008) | 1050 | 6 months | Etanercept (no. 455)
Infliximab (no. 450) | −308A/G
−238A/G | The −308AA genotype is significantly associated with a poorer response to ETA with respect to −308GG. This result is not present for Infliximab. The −238GA genotype is associated with a poorer response to Infliximab but not ETA |
|
| Ongaro et al. (2008) | 105 | 1 year | Etanercept (no. 55)
Infliximab (no. 40)
Adalimumab (no. 10) | −676G/T
−308A/G | No association was found between −308 genotype and clinical response.
The −676TG genotype is significantly associated with a lower response to anti-TNF therapy |
|
